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Objectives. This study sought to 1) develop an efficient treat-
ment protocol for postoperative automatic junctional tachycardia
(JT) using conventional drugs and techniques, and 2) identify
clinical features associated with this disorder by analyzing a large
study group.
Background. Postoperative JT is a transient arrhythmia that
may be fatal after operation for congenital cardiac defects. Its
precise cause is unknown. A variety of palliative treatments have
evolved, but because of a low incidence of JT, large studies of the
most efficient therapeutic sequence are lacking.
Methods. A protocol for rapid JT (>170 beats/min) was
adopted in 1986, and was tested in 71 children between 1986
and 1994. Staged therapy involved 1) a reduction of cat-
echolamines; 2) correction of fever; 3) atrial pacing to restore
synchrony; 4) digoxin; 5) phenytoin or propranolol or vera-
pamil; 6) procainamide or hypothermia; and 7) combined
procainamide and hypothermia. Effective therapy was defined
as a sustained reduction of JT rate <170 beats/min within 2 h.
Clinical profiles of the study group were contrasted with all
patients without JT from this same era to identify features
associated with JT.
Results. Of the multiple treatment stages, only correction of
fever and combined procainamide and hypothermia appeared to
be efficacious. By refining the protocol to eliminate nonproductive
stages, the time to JT control was significantly shortened for the
last 30 patients. Treatment was ultimately successful in 70 of 71
children. Postoperative JT was strongly associated with young age,
transient atrioventricular block and operations involving ventric-
ular septal defect closure.
Conclusions. A staged approach to therapy, with emphasis on
combined hypothermia and procainamide in difficult cases, ap-
pears to be an effective management strategy for postoperative JT.
These results may also serve as comparison data for evaluation of
newer and promising JT options, such as intravenous amioda-
rone. Trauma to conduction tissue may play a central role in the
etiology of this disorder.
(J Am Coll Cardiol 1997;29:1046–53)
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Junctional tachycardia (JT) is an uncommon arrhythmia
thought to arise from abnormal automaticity at the atrioven-
tricular (AV) node or proximal His bundle (1,2). In children, it
may occur as a primary idiopathic disorder (3) but is seen more
often as a transient phenomenon immediately after surgery for
congenital heart defects (1,4). Although mildly elevated junc-
tional rates are well tolerated in the postoperative setting,
rapid JT can result in hemodynamic compromise or death, and
remains among the more difficult tachycardias to control.
Fortunately, it will usually resolve spontaneously within hours
or days if the patient can be supported by restoring AV
synchrony and slowing the junctional rate to a physiologic
range. A variety of interventions have evolved to accomplish
these goals, including pacing maneuvers (5,6), pharmacologic
therapy (7–11), induced hypothermia (12–14) and even His
bundle ablation (15). With this array of options, postoperative
JT can now be managed successfully in most patients, but
systematic study of the most efficient treatment sequence has
not been performed in a large group. This report expands
significantly the clinical experience with postoperative JT by
describing results of a staged therapeutic protocol used in 71
consecutive patients at Children’s Hospital in Boston from
1986 to 1994.
Methods
Protocol development. A management plan for rapid JT
was designed in 1986 (Fig. 1A) based on published recommen-
dations (4,7,12) and institutional experience (16). Periodic
modifications were made to the original protocol as prelimi-
nary data were reviewed, leading to a refined scheme (Fig. 1B)
that was adopted in 1990 and remained in effect until study
completion in 1994. Intravenous propafenone was not avail-
able at the hospital during this period, and intravenous amio-
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darone was used in just one patient under a compassionate use
protocol.
Patient selection and diagnosis of JT. The diagnosis was
based on established electrocardiographic (ECG) criteria (1),
including 1) QRS configuration similar to conducted sinus or
atrial paced beats; 2) rapid ventricular rate greater than or
equal to atrial rate, usually exhibiting a pattern of “warm up”
at initiation; and 3) atrial activity in the form of dissociated
sinus rhythm or retrograde conduction in patterns of 1:1 or
Wenckebach. If atrial timing was indistinct on the surface
ECG, electrograms were recorded from pacing wires or an
esophageal lead. In cases where the A/V ratio was 1:1 or
tachycardia onset seemed abrupt, or both, attempts were made
to exclude a reentrant mechanism with atrial pacing maneu-
vers, intravenous adenosine or electrical cardioversion. Abrupt
tachycardia termination in response to any of these measures
was considered incompatible with a diagnosis of automatic JT,
and such patients were excluded.
Patients with a confirmed diagnosis were included in this
study only if JT was faster than 170 beats/min. This value was
chosen based on our institutional experience, which suggested
that JT begins to exert deleterious hemodynamic effects at or
above this rate. Patients with slower JT were excluded, as were
those already receiving a class I or class III antiarrhythmic drug
for any condition.
The study group included 71 patients. The initial 41,
managed from 1986 to 1990, were followed prospectively from
the time of JT diagnosis until hospital discharge. Data from
these patients were used to generate protocol modifications,
which led to the final treatment plan adopted in 1990. Infor-
mation from an additional 30 consecutive patients treated
according to the final protocol from 1990 to 1994 was obtained
by retrospective chart review. Clinical features of these 71
patients with JT were then compared with all cardiac surgical
patients without JT from this same era. Data on the group
without JT were obtained from departmental computer
records.
Treatment protocol (Fig. 1). Therapy began with general
efforts to optimize hemodynamic variables, respiratory status,
electrolyte status and sedation. Attempts were also made to
discontinue catecholamine infusions whenever the hemody-
namic status allowed. In addition, any patient with a temper-
ature .38°C was treated with acetaminophen or a cooling
blanket to establish normothermia.
If rapid JT persisted, therapy was begun to restore AV
synchrony and slow the junctional rate. Synchrony was
achieved with atrial pacing at a rate slightly faster than JT
using epicardial wires or an esophageal lead. The pacemaker
rate was manually adjusted at frequent intervals to maintain
the minimal rate for effective synchrony. Atrial pacing was not
used as isolated therapy unless (or until) the JT rate was ,200
beats/min.
Direct therapy to slow the junctional rate with drugs or
hypothermia was administered promptly to all patients with JT
.200 beats/min or to any patient with persistently elevated
rates (170 to 200 beats/min) after a trial of atrial pacing.
Digoxin. For patients not receiving digoxin preoperatively,
half of a total digitalizing dose was administered intravenously,
with full digitalization over the next 8 to 24 h. Patients
receiving the drug preoperatively were given intravenous main-
tenance doses of 5 mg/kg every 12 h. Digoxin was eliminated
from the protocol in 1990 after review suggested minimal
efficacy.
Class IB (phenytoin) class II (propranolol) or class IV
(verapamil). These agents were tested only during the early
months of the protocol (10 trials in six patients). Propranolol
and verapamil were restricted to nonhypotensive patients, and
verapamil was further restricted to patients over 1 year of age.
Intravenous dosages involved phenytoin (10 mg/kg body
weight over 20 min), propranolol (0.1 mg/kg over 20 min) and
verapamil (0.05 to 0.1 mg/kg over 1 to 5 min). These drugs
were abandoned in 1987 because of a lack of efficacy.
Procainamide. Administration began as a bolus of 5 to
15 mg/kg over 15 to 30 min followed by an infusion of 20 to
Abbreviations and Acronyms
AV 5 atrioventricular
ECG 5 electrocardiogram
JT 5 automatic junctional tachycardia
TOF 5 tetralogy of Fallot
VSD 5 ventricular septal defect
Figure 1. Outline of initial protocol (A) and refined protocol (B) for
management of rapid postoperative JT, used from 1986 to 1994. (See
text for details.) Hypo 5 hypothermia; IV 5 intravenous; Proc 5
procainamide.
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80 mg/kg per min, aiming for a serum procainamide level of 4
to 10 mg/ml. The infusion was stopped at 12-h intervals to
evaluate the necessity for continued use. Procainamide was
eliminated as an isolated therapy in 1989 based on an early
unfavorable comparison with the results for hypothermia, but
was still retained as part of combination therapy.
Hypothermia. Core temperature was reduced to 33 to 35°C
using a posterior cooling blanket, with the patient sedated,
mechanically ventilated and paralyzed to prevent shivering.
Temperature was continuously monitored through a rectal or
esophageal thermistor. Patients were allowed to rewarm at
12-h intervals to examine the underlying rhythm. Hypothermia
remained an active stage of the protocol for the duration of the
trial.
Combined procainamide and hypothermia. Combined ther-
apy involved the drug dosage and cooling technique outlined
under Procainamide and Hypothermia. Combined therapy was
retained in the protocol for the duration of the trial.
Amiodarone. Intravenous amiodarone was administered in
one patient under a compassionate use protocol with emer-
gency approval of the hospital Committee on Clinical Investi-
gation and parental consent. A single dose of 5 mg/kg was
given over 30 min.
Evaluation of treatment response. In an effort to minimize
the influence of spontaneous JT resolution on perceived
treatment response, effective therapy was strictly defined as one
which 1) decreased the JT rate ,170 beats/min within 2 h, and
2) was not associated with any subsequent rate rebound .170
beats/min. Therapy was defined as possibly effective if 1) the
time until JT slowing ,170 beats/min was delayed beyond 2 h
but the patient responded well thereafter and did not require
escalation to a higher stage of the protocol, or 2) there were
late increases in the JT rate .170 beats/min after at least 6 h
of a good early response, whether or not therapy was escalated.
Ineffective therapy was defined as accelerated or persistently
rapid (.170 beats/min) JT requiring escalation of therapy.
Two time variables were recorded for each patient: the time to
JT control (when sustained rate slowing ,170/min was
achieved) and the time to JT resolution (when junctional
automaticity abated and sinus rhythm returned).
Statistics. Data are presented as mean value 6 SD along
with median value when appropriate. The chi-square and
Fisher exact tests were used to compare categoric variables.
Comparison of values for cardiopulmonary bypass time and
serum procainamide levels was performed using the unpaired
t test. For comparisons of time to JT control and time to JT
resolution, the log-rank test was performed. A level of p , 0.05
was considered significant.
Results
Patient characteristics. Between May 1986 and October
1994, a total of 71 postoperative patients were identified with
JT .170 beats/min, representing 1% of all cardiac surgical
patients during that period. Ages were 1 day to 18 years
(median 4 months, mean 12 6 28 months). According to the
preoperative ECG, all patients were in sinus rhythm, and AV
conduction was normal for all but one patient with first-degree
block and one with right bundle branch block. Twenty-seven
patients (38%) were receiving digoxin preoperatively, and one
was receiving propranolol. Cardiopulmonary bypass time was
119 6 50 min (n 5 69), which was not significantly different
from the bypass duration of 125 6 32 min reported by our
institution for other large surgical groups (17). Two patients
developed JT after procedures that did not involve bypass;
both had transposition/intact septum and underwent isolated
pulmonary artery banding to prepare the left ventricle for
anticipated arterial switch operation.
When the 71 patients with JT were compared with the
non-JT group by surgical subcategory (Table 1), there was a
Table 1. Clinical Features of Patients With and Without Automatic
Junctional Tachycardia, 1986–1994
Diagnosis
With JT (n 5 71)
(age 12 6 28 mo)
Without JT (n 5 7,010)
(age 48 6 72 mo)
No. of
Pts
Mean (6SD)
age (% , 1 yr)
No. of
Pts
Mean (6SD)
age (% , 1 yr)
Positive association
TOF 26* 6 6 9 mo (88%*) 910 34 6 60 mo (53%)
VSD 16* 5 6 3 mo (94%†) 674 29 6 56 mo (63%)
TGA/VSD 9† 2 6 4 mo 198 7 6 13 mo
Truncus 4† 4 6 6 mo 90 7 6 17 mo
No association
Fontan 6 29 6 17 mo 585 68 6 66 mo
TGA/IVS 1 3 mo 381 2 6 13 mo
CAVC 4 5 6 1 mo 259 15 6 30 mo
Caval-PA shunt — — 253 45 6 62 mo
PDA — — 238 8 6 20 mo
Norwood/Stansel 1 1 mo 235 1 6 4 mo
AO valve — — 211 134 6 102 mo
AV valve 1 5 mo 153 40 6 60 mo
ASD primum — — 151 60 6 103 mo
PA band 2 42 6 59 mo 126 10 6 30 mo
P vein — — 112 21 6 78 mo
P valve/art — — 103 52 6 74 mo
Rastelli 1 32 mo 59 51 6 54 mo
Transplant — — 39 120 6 106 mo
Negative association
ASD secundum —‡ — 421 42 6 67 mo
Coarct/arch —‡ — 414 27 6 53 mo
Pacemaker —‡ — 391 144 6 120 mo
Syst-PA shunt —‡ — 353 19 6 50 mo
Miscellaneous — — 654 64 6 84 mo
*p , 0.001, †p , 0.01 and ‡p 5 0.02 to 0.05 compared with patients without
JT. AO 5 aortic; ASD 5 atrial septal defect; AV 5 atrioventricular; Caval-PA
shunt 5 caval to pulmonary shunt (Glenn and variants); CAVC 5 common
atrioventricular canal; Coarct/arch 5 coarctation and other aortic arch surgery;
PA 5 pulmonary artery; P valve/art 5 pulmonary valvular or arterial repair or
plasty; P vein 5 total or partial anomalous pulmonary venous return; PDA 5
patent ductus arteriosus; Syst-PA shunt 5 systemic to pulmonary arterial shunt;
TOF 5 tetralogy of Fallot and variants; TGA/IVS 5 atrial (n 5 46) or arterial
(n 5 335) switch for transposition with intact ventricular septum; TGA/VSD 5
atrial (n 5 6) or arterial (n 5 192) switch for transposition plus closure of
ventricular septal defect; VSD 5 membranous or muscular ventricular septal
defect.
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strong association between JT and operations involving ven-
tricular septal defect (VSD) closure, especially tetralogy of
Fallot (TOF) repair. For most extracardiac operations (e.g.,
coarctation) and some intracardiac operations (e.g., atrial
septal defect), a negative association was evident. The inci-
dence of JT in the remaining subcategories (e.g., Fontan
procedure) did not reach statistical significance.
The mean age at operation (Table 1) was younger for
patients with JT compared with patients without it, both
overall and within most of the relevant surgical subcategories.
In addition, among patients with TOF and VSD (the two
surgical subcategories with the majority of JT cases), the
proportion of patients under 1 year of age (Table 1) was
significantly higher for those with JT compared with those
without it.
Although 54 patients (76%) were receiving intravenous
catecholamines at the time of JT onset, in most cases the agent
was dopamine at a low dose of ,5 mg/kg per min. Only 29%
were receiving multiple or high dose infusions. Arterial blood
gases and serum chemistry data were generally normal at the
time of JT onset, with the exceptions of hypokalemia in four
patients, hypercapnia in one and metabolic acidosis in one.
Correction of these abnormalities did not abolish JT.
A notable postoperative finding was a high incidence of
transient AV block, which occurred in 14 of the JT patients
(20%). The duration ranged from 1 hour to 10 days, but no
patient had permanent block. Rapid JT began at the same time
as the return of AV conduction in seven patients, before
recovery of conduction in three and sometime after in four.
This incidence of transient AV block was significantly higher
(p , 0.001) than the 2% value observed at our institution for
the general cardiac surgical population (18).
Characteristics of JT. Tachycardia typically began in the
operating room or soon after arrival in the intensive care unit
(median 5 h, mean 21 6 34 h) but was delayed as late as
postoperative day 7 in one child. Peak junctional rates ranged
from 170 to 300 beats/min (mean 205 6 23). The QRS patterns
during JT included narrowing (31%), incomplete right bundle
branch block (10%), complete right bundle branch block
(58%) and bifascicular block (1%). For all but one patient with
a prolonged QRS complex during JT, the conduction delay was
surgically induced and was a permanent rather than a rate-
related aberration. There was complete ventriculoatrial disso-
ciation during tachycardia in 87% of patients, whereas the
remaining 13% exhibited retrograde conduction in a 1:1 or
Wenckebach pattern.
Hemodynamic variables. The technical/anatomic result of
the operation was satisfactory for 85% of the patients with JT.
Only 15% had a clinically significant residual hemodynamic
defect: dilated systemic ventricle with impaired systolic func-
tion (n 5 4), moderate or severe AV valve regurgitation (n 5
3), elevated right-sided pressures in a Fontan circulation (n 5
3) and pulmonary venous obstruction (n 5 1).
For 35 patients in whom pressure data were available
before and after the onset of JT, systolic arterial blood
pressure decreased by a mean of 19 6 13 mm Hg, and atrial
pressures increased by a mean of 4 6 3 mm Hg in tachycardia.
For the remaining patients, the onset of JT was too early in the
postoperative course to establish valid comparison data for
baseline sinus rhythm. Once JT control was achieved, all
patients had arterial and atrial pressures that were physiolog-
ically appropriate for age and type of repair.
Results for staged therapy. All 71 patients were treated
initially with general supportive measures. The influence of
these diverse interventions could not be well quantified, with
two exceptions: discontinuation of catecholamine infusions,
which was attempted in 16 patients, and establishment of
normothermia in 17 patients with fever. Scored results for
these and other interventions are shown in Figure 2.
Pacing maneuvers to restore AV synchrony were used as
isolated therapy in 18 patients, but were scored as effective in
only five. Pacing was also used as adjunctive therapy in an
additional 44 patients receiving simultaneous medications or
hypothermia, in which case the isolated influence of AV
synchrony could not be evaluated.
The initial pharmacologic intervention aimed at slowing JT
in the early years of the protocol was digoxin, which was tested
in 31 patients and was largely ineffective (Fig. 2). The JT rates
for individual patients over the hours after digoxin administra-
tion are charted in Figure 3A. Trials of either a class IB, II or
Figure 2. Results of treatment stages for JT in 71 patients.
Interventions are arranged (left to right) in general order
of testing. Most patients needed to progress through
multiple stages of therapy, but an effective (n 5 63) or
possibly effective (n 5 7) treatment was ultimately found
in 70 of 71 patients. 2Cat 5 decrease catecholamine
infusion; Fever 5 establishment of normothermia for
febrile patients; Sync 5 atrial pacing to restore AV
synchrony; Dig 5 digoxin; IB, II, IV 5 class IB (phenytoin
[Dilantin]), class II (propranolol) or class IV (verapamil)
agent; Proc 5 procainamide; Hypo 5 hypothermia; Comb.
5 combined hypothermia and procainamide; Poss. Eff. 5
possibly effective.
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IV agent were performed on 10 occasions early in the protocol
and had little impact on JT. Procainamide was tested as an
isolated therapy in nine patients. Despite the lack of long-term
efficacy, there was a pattern suggesting acute JT slowing
immediately after procainamide loading with a later rebound
at 2 to 6 h, as shown in Figure 3B. The serum procainamide
level for the “effective” or “possibly effective” subgroup was
3.9 6 1.6 mg/ml, compared with 5.9 6 1.6 mg/ml in the
“ineffective” subgroup, making dose-related failure unlikely.
Intravenous amiodarone was used in only one patient. A single
loading dose of 5 mg/kg did not alter the JT rate, and
long-term infusion was not tested.
Induced hypothermia was tested in 38 patients, with prom-
ising but inconsistent results (Fig. 2). A positive response was
generally prompt (Fig. 3C), such that efficacy (or lack thereof)
could be predicted within 1 or 2 h. Combined hypothermia and
procainamide was tested in 30 patients and resulted in the
most consistent JT control, with effective trials in 80% (Fig.
3D). The mean procainamide level for patients on combined
therapy was 4.6 6 2.5 mg/ml, which was nearly identical to that
of patients receiving procainamide alone, despite the differ-
ence in efficacy.
The individual stages of therapy were evaluated statistically
(Table 2) by comparison with the results for digoxin (assuming
digoxin efficacy was negligible). Only normothermia and com-
bined hypothermia and procainamide were significantly better
than digoxin when only effective trials were considered as
treatment success. If both effective and possibly effective trials
were combined, normothermia, procainamide, hypothermia
alone and combined hypothermia and procainamide were
superior to digoxin.
Patient outcome. In 70 of 71 patients, JT was managed
successfully. This was accomplished in 63 patients with an
intervention scored as effective. In seven other patients who
ultimately had good JT control, the therapeutic response was
delayed beyond 2 h (n 5 3) or was associated with later
self-limited acceleration of JT (n 5 4), and was thus considered
possibly effective. The time to JT control for the total group
was variable (range 1 to 69 h, mean 5.6 6 11, median 3), in part
reflecting the time spent early in our experience with trials of
ineffective therapy. For the last 30 patients treated according
to the refined protocol between 1990 and 1994, the time to
control (mean 2.9 6 2 h, median 2) was significantly shorter
Figure 3. Time course for JT rates in individual patients during
selected stages of therapy. The goal of treatment was to achieve a
sustained reduction in the JT rate ,170 beats/min (dashed horizontal
line). Patients remained on a given stage of therapy for variable
periods and exited the stage at the time of either 1) resolution of JT;
2) escalation to another therapeutic stage; or 3) death. (See text for
definitions of efficacy.)
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(p 5 0.04) than the time to control for the first 41 patients
(mean 7.7 6 15 h, median 3). The time to complete resolution
of JT ranged from 2 to 168 h (mean 39 6 38, median 36) and
did not differ significantly between the original and refined
protocol (mean 49 6 42 h vs. 32 6 34 h).
Treatment failed in one patient despite all levels of therapy.
This patient was a 3-year old with a palliated hypoplastic left
heart who underwent a Fontan procedure and had a postop-
erative course complicated by low cardiac output and meta-
bolic acidosis. Despite hypothermia and procainamide, the
patient ultimately died with continued low output and widely
fluctuating JT rates of 140 to 190 beats/min. There were seven
more hospital deaths that occurred in the setting of either
resolved (n 5 3) or well-controlled JT (n 5 4), all of which had
a cardiopulmonary explanation unrelated to rhythm status.
There were three complications potentially associated with
therapy. Two children with effective JT control had acute
ventricular fibrillation—one while on procainamide alone (se-
rum level 3.0 mg/ml) and one while on combined therapy with
procainamide (serum level 4.0 mg/ml) and hypothermia
(33.8°C). Torsade de pointes was not documented in either
case, and QT intervals were not prolonged. Both patients
responded to electrical defibrillation and were maintained on
the same JT therapy without recurrence of ventricular arrhyth-
mias. One other patient, who was successfully managed with
combined hypothermia and procainamide for 24 h, developed
severe respiratory distress syndrome 48 h after return of
normal sinus rhythm. The patient recovered but a contributory
role for hypothermia in this atypical pulmonary process could
not be ruled out.
Discussion
The central findings of this study are that 1) staged therapy
(with an emphasis on combined hypothermia and procain-
amide in difficult cases) is an effective management approach
for rapid postoperative JT; and 2) postoperative JT is strongly
associated with young age, procedures that involve VSD
closure and transient AV block. As newer treatment options
such as intravenous amiodarone become more widely avail-
able, a reappraisal of JT management strategy has begun at
many centers, including our own. The information from this
report, which concentrated on “traditional” techniques for JT
control, may serve the additional function of a comparison
data base for prospective evaluation of alternate therapy.
Treatment of postoperative JT. No single stage of therapy
was universally effective in this experience, and in fact, some
commonly recommended JT treatments had minimal demon-
strable value. Such was the case with digoxin, where the few
effective trials probably represented the natural history of
spontaneous JT resolution rather than drug effect. By elimi-
nating digoxin and other nonproductive stages from the orig-
inal protocol, a more efficient plan emerged, which significantly
shortened the time to JT control. The observation that time to
control could be shortened, without changing overall JT dura-
tion, strongly supports a true therapeutic effect for the refined
protocol, rather than a natural history phenomenon.
There was practical merit to initiating treatment with
simple measures, including reduction of exogenous cat-
echolamines, pacing to restore AV synchrony and establish-
ment of normothermia for febrile patients. Among these, only
fever control seemed to have identifiable efficacy by statistical
analysis. Nonetheless, these general measures could be tested
quickly, had no obvious toxicity and were the only necessary
therapy for 24% of our study group. All should be retained as
first-line JT treatments, even if success is sporadic with cate-
cholamine reduction and pacing. When AV synchrony was
used in conjunction with drug therapy or hypothermia, or both,
during this protocol, it was difficult to assess the isolated
impact of pacing, but it seems likely that it was beneficial. This
impression is reinforced by the study of Till and Rowland (6),
who observed that AV synchrony provided additional hemo-
dynamic benefit for patients already treated with drugs or
hypothermia to reduce JT rates.
Hypothermia provided an effective reduction in JT rates for
21% of our patients, but ineffective trials remained common.
Fortunately, failures of hypothermia could be predicted early
into cooling, allowing therapy to be escalated without much
delay. These data differ from the more optimistic results with
hypothermia reported by Pfammatter et al. (14) in a series of
six patients, perhaps because of the more rigorous definition of
efficacy and the larger patient group used in the present study.
Table 2. Efficacy of Therapeutic Stages for Rapid Postoperative Automatic Junctional Tachycardia
Therapy
Effective
Trials
p
Value*
Effective and Possibly
Effective Trials
p
Value*
Digoxin (n 5 31) 7/31 (22%) — 9/31 (29%) —
scatecholamines (n 5 16) 3/16 (19%) NS 4/16 (25%) NS
Normothermia (n 5 17) 10/17 (59%) 0.01 13/17 (76%) 0.002
AV synchrony (n 5 18) 5/18 (28%) NS 10/18 (56%) NS
Class IB, II, IV (n 5 10) 0/10 (0%) NS 2/10 (20%) NS
Procainamide (n 5 9) 2/9 (22%) NS 5/9 (67%) 0.04
Hypothermia (n 5 38) 12/38 (32%) NS 22/38 (58%) 0.02
Procainamide and hypothermia
(n 5 30)
24/30 (80%) , 0.001 29/30 (97%) , 0.001
*Compared with results with digoxin.
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Combined hypothermia and procainamide provided the
most reliable reduction of JT rate in our experience, and was
ultimately the sole effective therapy for nearly half of the
patients. It is notable that procainamide under normothermic
conditions had less influence on the tachycardia, suggesting a
temperature-dependent action (19) of this agent on the mem-
brane channel(s) involved. Some investigators (10) have re-
cently advocated use of high dose procainamide for JT,
although review of drug levels in our patients did not support
dose-related efficacy.
Successful JT slowing has also been reported with intrave-
nous propafenone (8) and intravenous amiodarone. The single
failure of amiodarone in our study would seem to be an
unusual outcome compared with the experience of Raja et al.
(11), who observed satisfactory reduction in JT rates after 2 h
of therapy in 10 (62%) of 16 patients. Because of concerning
alterations in hemodynamic variables and immune status that
may accompany prolonged hypothermia (20,21), any agent that
can function well under normothermic conditions needs to be
seriously explored, assuming equivalent efficacy can be dem-
onstrated. It would be hazardous to compare patient outcome
in this report to published results for propafenone and amio-
darone, because the definitions of successful therapy were not
standardized. This issue should be addressed in a prospective
manner.
In truly refractory cases of postoperative JT, ablation may
have a role. Radiofrequency catheter ablation has proved
useful in managing the congenital form of JT (22), and
successful surgical cryoablation has been reported in one case
of postoperative JT (15). Although it is sometimes possible to
eliminate congenital JT without interrupting normal AV con-
duction (23), it is uncertain whether postoperative JT can be
ablated without AV block. The risk of pacemaker dependency
must be balanced against the self-limited nature of postoper-
ative JT whenever ablation is considered.
Etiology of postoperative JT. Previous investigators have
noted the tendency for JT to occur after surgery involving
manipulation near the proximal conduction system, such as
TOF repair and other forms of VSD closure (6,7,9,11,13,14).
However, because these procedures account for a high per-
centage of cardiac operations in children, and because the
number of patients with JT in previous reports was small, it has
been difficult to test the statistical strength of this association.
Analysis of the larger group in the current study strongly
supports past clinical impressions and demonstrates that sur-
gery incorporating VSD closure is significantly associated with
JT. In contrast, JT was uncommon in the absence of VSD
closure, regardless of whether the operation involved an
intracardiac or extracardiac procedure. In addition, the high
incidence of transient postoperative AV block noted in the JT
group is consistent with the idea that trauma to the AV node
or His bundle is key to the pathogenesis of JT, related either to
suture placement during VSD closure or to stretch injury
incurred while gaining surgical exposure. Finally, the associa-
tion of younger age with JT may further support the concept of
suture or stretch injury to the proximal AV conducting system,
because there is less room for surgical manipulation in the
smaller heart. Despite these findings, JT was also seen in 10
study patients (14%) in whom direct manipulation near con-
duction tissue seemed less likely: Fontan operation (n 5 6),
pulmonary artery banding (n 5 2), Senning procedure (n 5 1)
and Norwood operation (n 5 1). This inconsistency highlights
the need for continued study of both the cellular mechanism
and pathogenesis of JT. Potential directions for investigation
include better quantitation of intraoperative trauma or stretch
near the crux of the heart, as well as analysis of novel
postoperative variables such as a recent report of elevated
histamine levels among some patients with postoperative JT
(24).
Study limitations. The major limitation of this study in-
volves the self-resolving nature of postoperative JT, which
confounds the distinction between natural history and thera-
peutic effect. In addition, therapy was tested according to a
staged rather than a randomized design. We used consistent
definitions of efficacy in an effort to minimize these issues, but
recognize that the use of patients as their own controls during
staged treatment limits the strength of the analysis.
An important question not addressed by this study is
whether aggressive therapy is always indicated for rapid JT.
Based on previous reports (7) and institutional experience
suggesting a poor prognosis for untreated JT, we adopted a
policy to treat all patients with rates .170 beats/min. This may
or may not be a valid approach. Some centers prefer to follow
patients with JT conservatively and have reported good out-
comes with minimal intervention (25). Attempts to quantify
the hemodynamic effects of JT and the benefits of therapy in
the present study were difficult, but in agreement with most
other investigators (5–14), we observed trends toward lower
arterial blood pressure and higher atrial pressures when rapid
JT began, which reversed when the rate was controlled and AV
synchrony was restored. However, the more meaningful vari-
ables to measure in patients with JT involve mixed venous
saturation or cardiac output, which were not part of the current
or any previous JT study design. Cardiac output determination
may be most critical when hypothermia is employed because
increased systemic resistance is known to occur at tempera-
tures of 31 to 35°C (20). We have now begun to rely on routine
sampling of mixed venous saturations as a more objective
measure of the necessity for (and effects of) JT treatment,
rather than responding to rate alone.
Conclusions. Expeditious treatment of postoperative JT
requires a large arsenal of treatment options. We describe one
possible scheme that served a large group of patients well over
the course of an 8-year trial, using a sequence of readily
available drugs and techniques. Intravenous amiodarone may
also be a reliable option, and data are now accumulating
regarding its efficacy in this setting (11,26–28). Still lacking
from all management plans is a therapy that restores sinus
rhythm directly, rather than palliating the condition during the
hours or days required until junctional automaticity resolves.
Definitive therapy may remain elusive until the precise cause
and cellular mechanism of JT are better understood.
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